Mealey's (April 13, 2023, 1:48 PM EDT) -- SAN FRANCISCO — Corcept Therapeutics Inc. will pay $14 million to settle class claims in which shareholders allege that the drug maker and certain of its senior executives engaged in an improper off-label marketing scheme for the use of Korlym, a brand name version of the abortion drug mifepristone, for the treatment of endogenous Cushing’s syndrome, according to a motion for preliminary approval of the settlement filed in California federal court....